CRISPR Therapeutics Reports Deep, Durable Lipid Lowering from In Vivo Gene Editor CTX310 in Phase 1a Trial

September 6, 2026

MarketScreener (CRISPR Therapeutics) Switzerland

Overview

CRISPR Therapeutics AG announced compelling one-year durability data from its Phase 1a clinical trial of CTX310, an in vivo CRISPR/Cas9 gene-editing therapy targeting ANGPTL3. A single dose of CTX310 demonstrated deep and sustained reductions in ANGPTL3, triglycerides, and LDL cholesterol over a full year. At the highest dose, patients achieved average reductions of 79% in ANGPTL3, 48% in triglycerides, and 53% in LDL, highlighting its potential as a transformative treatment for dyslipidemia.

In Depth

Background

Dyslipidemia, characterized by elevated levels of triglycerides and LDL cholesterol, is a major risk factor for cardiovascular diseases, which remain a leading cause of morbidity and mortality worldwide. Current treatments often require lifelong medication. In vivo gene editing, particularly with CRISPR/Cas9 technology, offers the potential for a single-administration therapeutic solution by permanently altering genes responsible for lipid metabolism, such as ANGPTL3 (Angiopoietin-like 3).

Key Findings

CRISPR Therapeutics AG presented long-term durability data from its Phase 1a clinical trial for CTX310, an in vivo CRISPR/Cas9 gene-editing therapy.
CTX310 targets the ANGPTL3 gene, aiming to reduce its expression, which is known to influence lipid levels.
A single administration of CTX310 resulted in deep and durable reductions in ANGPTL3 protein, triglycerides, and LDL cholesterol levels, which were sustained for a full one-year period.
Specifically, at the highest tested dose, patients demonstrated an average reduction of 79% in ANGPTL3 levels.
Concurrently, triglyceride levels decreased by an average of 48%, and LDL cholesterol levels saw an average reduction of 53%.

Significance & Outlook

These Phase 1a results for CTX310 are highly significant, demonstrating the potential of in vivo CRISPR-based gene editing to provide a single-dose, durable therapeutic effect for hyperlipidemia. The profound and sustained reductions in ANGPTL3, triglycerides, and LDL cholesterol achieved with CTX310 could revolutionize the management of severe dyslipidemia, potentially reducing the lifelong burden of daily medication for patients and substantially lowering their risk of cardiovascular events. This data strengthens the case for gene-editing therapies as a transformative approach to chronic metabolic diseases. Future studies, including larger Phase 2 trials, will focus on confirming these effects across broader patient populations and further characterizing the safety profile, paving the way for a potential paradigm shift in lipid management.

Source: https://www.marketscreener.com/news/crispr-therapeutics-ag-presents-phase-1a-data-for-ctx310-demonstrating-deep-and-durable-angptl3-edit-ce7858dfd18afe27

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.